Table 2.

Patient characteristics grouped by PSA failure

Patient characteristics	All (N = 768)		DM
			No (n = 746)		Yes (n = 22)
	N	%	N	%	N	%
Age at diagnosis
≤ 67	395	51.4	362	50.6	33	62.3
> 67	373	48.6	353	49.4	20	37.7
Pre-treatment PSA
< 10	505	65.8	475	66.4	30	56.6
10-20	195	25.4	178	24.9	17	32.1
≥ 20	68	8.9	62	8.7	6	11.3
Gleason score
≤ 6	406	52.9	393	55	13	24.5
7	264	34.4	241	33.7	23	43.4
≥ 8	98	12.8	81	11.3	17	32.1
T-Stage
T1	287	37.4	275	38.5	12	22.6
T2	421	54.8	392	54.8	29	54.7
T3	60	7.8	48	6.7	12	22.6
Androgen deprivation
No	389	50.7	364	50.9	25	47.2
Yes	379	49.3	351	49.1	28	52.8
NCCN risk group
Low	197	25.7	191	26.7	6	11.3
Intermediate	383	49.9	363	50.8	20	37.7
High	188	24.5	161	22.5	27	50.9
Distant metastasis
No	746	97.1	707	98.9	39	73.6
Yes	22	2.9	8	1.1	14	26.4
Androgen deprivation
No	389	50.7	364	50.9	25	47.2
Yes	379	49.3	351	49.1	28	52.8
BED
≤ 234	492	64.1	450	62.9	42	79.2
> 234	276	35.9	265	37.1	11	20.8
HDR
22	113	14.7	103	14.4	10	18.9
24	655	85.3	612	85.6	43	81.1

BED – biologically equivalent dose